Choose your preferred way to stay informed of new case launches and settlement deadlines
The filed complaint alleges that Supernus Pharmaceuticals, Inc. made materially false and/or misleading statements and/or failed to disclose that: On February 19, 2025, The company announced that its Phase 2b study of SPN-820 for treatment-resistant depression failed to meet its primary endpoint, showing no significant improvement over placebo. This outcome comes as a surprise to investors, given the company's previous optimism surrounding the drug’s potential. Following this news, shares of Supernus Pharmaceuticals fell over 13% in trading.
In order to be eligible to join the SUPN class action lawsuit, you must have incurred a loss on shares of Supernus Pharmaceuticals, Inc. purchased during the class period listed above.
TOP
